Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 21, 2021

UCLH commences trial of new Alzheimer’s drug candidate

E2814 is the first tau-targeting treatment to enter trials in people with an inherited form of Alzheimer’s.

The University College London Hospitals (UCLH) in the UK has initiated a clinical trial of a new drug candidate, E2814, for the treatment of Alzheimer’s disease.

Developed at University College London (UCL) in collaboration with pharmaceutical company Eisai, E2814 can potentially address tau protein, which is present in the brain and causes disease progression.

UCLH noted that E2814 is the first therapy that targets tau to enter clinal trials in individuals with an inherited form of Alzheimer’s.

Subjects with a rare inherited form of the disease will be enrolled at UCLH Leonard Wolfson Experimental Neurology Centre.

The trial is being conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), a global partnership funded by Washington University School of Medicine to assess new investigational treatments for Alzheimer’s.

E2814 is the first therapy to enter the DIAN-TU tau study, UCLH noted.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The DIAN-TU tau programme plans to analyse a total of three anti-tau drugs in clinical trials to check for their ability to reduce or hinder Alzheimer’s disease progression.

UCL Dementia Research Centre clinical trials head Dr Cath Mummery said: “As we’ve learned more about Alzheimer’s, we understand that tau plays a critical role in disease progression alongside amyloid; this is the first anti-tau treatment we will study in these families with genetic forms of Alzheimer’s disease and this important work advances the field towards our goal of discovering an effective treatment for this devastating disease.”

If E2814 shows favourable efficacy in the DIAN-TU trial, it could benefit individuals with the more common, sporadic forms of Alzheimer’s in the elderly by slowing disease progression.

UCLH noted that people with inherited mutations that are responsible for Alzheimer’s typically develop cognitive impairments at an earlier age or around the same time when their parents did.

In July 2020, Eisai, Biogen and the Alzheimer’s Clinical Trials Consortium (ACTC) initiated a Phase III trial of BAN2401 to treat preclinical Alzheimer’s in the US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy